124 related articles for article (PubMed ID: 15114428)
41. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
[TBL] [Abstract][Full Text] [Related]
42. [Statins and muscular side-effects].
Brosteaux C; Ruiz J; Buclin T; Kuntzer T; Rodondi N
Rev Med Suisse; 2010 Mar; 6(239):510, 512-4, 516-7. PubMed ID: 20373698
[TBL] [Abstract][Full Text] [Related]
43. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Holoshitz N; Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2008 Jan; 101(1):95-7. PubMed ID: 18157972
[TBL] [Abstract][Full Text] [Related]
44. [Statins and muscular adverse effects].
Schjøtt J
Tidsskr Nor Laegeforen; 2000 Dec; 120(30):3729-31. PubMed ID: 11215947
[No Abstract] [Full Text] [Related]
45. Creatine phosphokinase values during isotretinoin treatment for acne.
Kaymak Y
Int J Dermatol; 2008 Apr; 47(4):398-401. PubMed ID: 18377609
[TBL] [Abstract][Full Text] [Related]
46. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
Jose J; Rao PG
Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
[TBL] [Abstract][Full Text] [Related]
47. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
48. [Non-traumatic rhabdomyolysis in medical practice].
Lionte C; Sorodoc L; Petriş O; Sorodoc V; Bologa C; Anton G
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1025-33. PubMed ID: 20191869
[TBL] [Abstract][Full Text] [Related]
49. [Muscular pain and hypolipidaemic drugs: a cross-sectional study in cardiological outpatient practice].
Biga J; Vigreux P; Lapeyre-Mestre M; Montastruc JL
Therapie; 2005; 60(3):295-7. PubMed ID: 16128273
[TBL] [Abstract][Full Text] [Related]
50. [Comparison of reports from patients and health professionals: statins and muscle disorders].
Laroche ML; Merle L
Therapie; 2005; 60(3):305-9. PubMed ID: 16128275
[TBL] [Abstract][Full Text] [Related]
51. Incidence and clinical spectrum of rhabdomyolysis in general neurology: a retrospective cohort study.
Paternostro C; Gopp L; Tomschik M; Krenn M; Weng R; Bointner K; Jäger F; Zulehner G; Rath J; Berger T; Zimprich F; Cetin H
Neuromuscul Disord; 2021 Dec; 31(12):1227-1234. PubMed ID: 34711480
[TBL] [Abstract][Full Text] [Related]
52. Utility of a Laboratory Alert System for Detecting Adverse Drug Reactions in Hospitalised Patients: Hyponatremia and Rhabdomyolysis.
Valdés-Garicano M; Mejía-Abril G; Campodónico D; Parra-Garcés R; Abad-Santos F
Front Pharmacol; 2022; 13():937045. PubMed ID: 35873584
[No Abstract] [Full Text] [Related]
53. [Analysis of antiretroviral drugs-induced adverse effects].
Baudrant M; Bagheri H; Cuzin L; Sommet A; Bassoua V; Guitton E; Bonnet E; Garipuy D; Lucas F; Aquilina C; Montastruc JL; Massip P
Therapie; 2006; 61(2):171-6. PubMed ID: 16886711
[TBL] [Abstract][Full Text] [Related]
54. Detecting Toxic Myopathies as Medication Side Effect.
Gerena-Maldonado E
Phys Med Rehabil Clin N Am; 2018 Nov; 29(4):659-667. PubMed ID: 30293621
[TBL] [Abstract][Full Text] [Related]
55. [Marked hypertransaminasemia incidence in a health department in the autonomous community of Valencia, Spain (2002-2003)].
Castillo-Gómez E; Colomina-Rodríguez J; Gimeno-Vilarrasa F; Moll-Navarro MJ; Guerrero-Espejo A
Rev Esp Salud Publica; 2007; 81(3):271-8. PubMed ID: 17694634
[TBL] [Abstract][Full Text] [Related]
56. Muscular disorders associated with cyclosporin.
Arellano F; Krupp P
Lancet; 1991 Apr; 337(8746):915. PubMed ID: 1672991
[No Abstract] [Full Text] [Related]
57. Monitoring abnormal laboratory values as antecedents to drug-induced injury.
Kane-Gill SL; Dasta JF; Schneider PJ; Cook CH
J Trauma; 2005 Dec; 59(6):1457-62. PubMed ID: 16394922
[TBL] [Abstract][Full Text] [Related]
58. On the reversibility of the biochemical reactions of muscular contraction during the absorption of negative work.
Mannherz HG
FEBS Lett; 1970 Oct; 10(4):233-236. PubMed ID: 11945400
[No Abstract] [Full Text] [Related]
59. [Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba].
Saad EJ; Rodríguez Ruiz A; Douthat Y Barrionuevo A; Milanesio M; Flores Balverdi J; Riscanevo NC; Peñaranda GE; Novatti EB; Saurit V; Alvarez AC; Baenas DF
Rev Fac Cien Med Univ Nac Cordoba; 2022 Dec; 79(4):327-333. PubMed ID: 36542584
[TBL] [Abstract][Full Text] [Related]
60. Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties.
Chwalenia K; Oieni J; Zemła J; Lekka M; Ahlskog N; Coenen-Stass AML; McClorey G; Wood MJA; Lomonosova Y; Roberts TC
Mol Ther Nucleic Acids; 2022 Sep; 29():955-968. PubMed ID: 36159597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
